Johnson & Johnson is normally a good buy for its dividend and the stability it offers. Over the past five years, however, the ...
Duato discusses the split of the business, dealing with the scrutiny brought about by lawsuits, and 2025 priorities.
Shares of Intra-Cellular Therapies are surging 35% in premarket trading Monday after Johnson & Johnson said it will acquire the biopharmaceutical company for roughly $14.6 billion.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback